| Literature DB >> 31130341 |
Ruidong Xue1, Lu Chen2, Chong Zhang1, Masashi Fujita3, Ruoyan Li1, Shu-Mei Yan4, Choon Kiat Ong5, Xiwen Liao6, Qiang Gao7, Shota Sasagawa3, Yanmeng Li1, Jincheng Wang1, Hua Guo8, Qi-Tao Huang4, Qian Zhong4, Jing Tan4, Lisha Qi9, Wenchen Gong9, Zhixian Hong10, Meng Li11, Jingmin Zhao12, Tao Peng6, Yinying Lu13, Kiat Hon Tony Lim14, Arnoud Boot15, Atushi Ono16, Kazuaki Chayama16, Zemin Zhang1, Steve George Rozen15, Bin Tean Teh17, Xin Wei Wang18, Hidewaki Nakagawa19, Mu-Sheng Zeng20, Fan Bai21, Ning Zhang22.
Abstract
We performed genomic and transcriptomic sequencing of 133 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) cases, including separate, combined, and mixed subtypes. Integrative comparison of cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarcinoma revealed that combined and mixed type cHCC-ICCs are distinct subtypes with different clinical and molecular features. Integrating laser microdissection, cancer cell fraction analysis, and single nucleus sequencing, we revealed both mono- and multiclonal origins in the separate type cHCC-ICCs, whereas combined and mixed type cHCC-ICCs were all monoclonal origin. Notably, cHCC-ICCs showed significantly higher expression of Nestin, suggesting Nestin may serve as a biomarker for diagnosing cHCC-ICC. Our results provide important biological and clinical insights into cHCC-ICC.Entities:
Keywords: Allen and Lisa; Nestin; bilinear differentiation; clonal origin; intratumor heterogeneity; liver cancer; metastatic route; molecular subtype; phenotypic transition; single nucleus sequencing
Mesh：
Substances：
Year: 2019 PMID： 31130341 PMCID： PMC8317046 DOI： 10.1016/j.ccell.2019.04.007
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743